Placenta extract injection aims to tame liver disease
NCT ID NCT06493799
First seen Feb 23, 2026 · Last updated May 06, 2026 · Updated 18 times
Summary
This phase 3 study tests a treatment called LAENNEC, made from human placenta, for people with chronic liver disease. It compares giving the drug through an IV drip versus a standard injection under the skin. The main goal is to see if the IV form lowers liver enzyme (ALT) levels more effectively over 6 weeks. About 226 adults with alcoholic or non-alcoholic fatty liver disease and elevated ALT will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GC wellbeing
RECRUITINGYongin-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.